In the wake of a dis­as­ter, Cem­pra shares shoot up on a promis­ing PhI­II an­tibi­ot­ic matchup

Just two months af­ter tak­ing a beat­ing on the FDA’s de­ci­sive re­jec­tion of Cem­pra’s an­tibi­ot­ic solithromycin, the biotech has been re­deemed by the suc­cess of a head-to-head Phase III matchup of its oral an­tibi­ot­ic fu­sidic acid against an old stand­by. Cem­pra’s shares $CEMP rock­et­ed up 40% on the turn­around.

Over­all, fu­sidic acid matched up fa­vor­ably to line­zol­id among the 716 pa­tients with acute bac­te­r­i­al skin and skin struc­ture in­fec­tions in the study, hit­ting its marks for non-in­fe­ri­or­i­ty and achiev­ing the pri­ma­ry as well a sec­ondary goals. Fu­sidic acid edged out line­zol­id among men and women, and matched up nice­ly for a range of in­fec­tion types.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER